Comparison Study of Computed Tomography-guided Radiofrequency and Microwave Ablation for Pulmonary Tumors: A Retrospective, Case-controlled Observational Study
Overview
Pulmonary Medicine
Affiliations
Background: The aim of this study was to compare the safety, efficacy, and prognostic value of radiofrequency ablation (RFA) and microwave ablation (MWA) for lung tumors.
Methods: Between March 2012 and January 2018, 238 patients with lung cancer were treated with MWA (139, 58.4%) or RFA (99, 41.6%) in our center. Patient and tumor characteristics, complications, complete ablation (CA) rate, and prognosis were compared between the groups. Meta-analysis was used to systematically compare the outcomes of RFA and MWA for the treatment of lung tumors.
Results: Ablation was successfully completed in all patients and no procedure-related death occurred. The total complication rates in the RFA and MWA groups were 24.2% (24/99) and 16.5% (23/139), respectively, and there was no statistically significant difference (P = 0.142). The initial and total CA rates were similar at P > 0.05 (RFA vs. MWA: initial CA, 97.0% vs. 96.4%; total CA, 99.0% vs. 98.6%, respectively). During follow-up, there was no significant difference in median progression-free (RFA vs. MWA: 12.5 months, 95% confidence interval [CI] 5.002-19.998 vs. 9.5 months, 95% CI 6.623-12.377; P = 0.673) or overall survival (RFA vs. MWA: 33 months, 95% CI 27.070-38.930 vs. 30 months, 95% CI, 18.482-41.518; P = 0.410) between the groups. Combined with the results of published comparison studies, meta-analysis further confirmed that the outcomes of these two treatments were similar.
Conclusion: Both RFA and MWA are safe and effective treatments with a survival benefit for selected patients with primary and metastatic lung tumors.
Advances in Image-Guided Ablation Therapies for Solid Tumors.
Campbell 4th W, Makary M Cancers (Basel). 2024; 16(14).
PMID: 39061199 PMC: 11274819. DOI: 10.3390/cancers16142560.
Application of Deep Learning for Real-Time Ablation Zone Measurement in Ultrasound Imaging.
Zimmermann C, Michelmann A, Daniel Y, Enderle M, Salkic N, Linzenbold W Cancers (Basel). 2024; 16(9).
PMID: 38730652 PMC: 11083655. DOI: 10.3390/cancers16091700.
Quang T, Yang J, Mikhail A, Wood B, Ramanujam N, Mueller J JCO Glob Oncol. 2023; 9:e2300155.
PMID: 37625104 PMC: 10581629. DOI: 10.1200/GO.23.00155.
Wang J, Li B, Zhang L, Wang Z, Shen J Eur Radiol. 2023; 34(1):236-246.
PMID: 37505251 DOI: 10.1007/s00330-023-09997-z.
Image-Guided Percutaneous and Transarterial Therapies for Primary and Metastatic Lung Cancer.
Mansur A, Garg T, Camacho J, Habibollahi P, Boas F, Khorshidi F Technol Cancer Res Treat. 2023; 22:15330338231164193.
PMID: 36942407 PMC: 10034348. DOI: 10.1177/15330338231164193.